Chapter 8

Novel Antidepressant Targets for Cognitive Dysfunction in Major Depressive Disorder

Beatrice Bortolato and Andre F. Carvalho


Cognitive dysfunction in MDD represents one of the most frequent residual symptoms persistently following the achievement of symptomatic remission. Moreover, emerging evidence indicates that significant cognitive deficits occur early in the course of the disorder and may persist during affective remission. Cognitive impairment lowers the likelihood of achieving the functional recovery. Conventional antidepressant treatments exert a beneficial yet unsatisfactory effect on cognitive dysfunction in MDD. As a consequence, the recognition of treatments capable of specific cognitive improvements is an unmet need. Vortioxetine, a multimodal antidepressant, has cognitive enhancing properties that seem to occur independently of affective improvement. Several routes of research are evaluating the potential of several pharmacological and non-pharmacological interventions in improving cognitive performance. Agents under investigation include lisdexamfetamine, glutamatergic modulators, erythropoietin, anti-inflammatory agents as well as nutraceuticals, such as omega-3-polyunsaturated fatty acids, S-adenosyl-methionine and melatonin. Moreover, neuromodulatory, psychological and biobehavioural approaches provided preliminary encouraging results. However, further investigations are warranted to confirm these findings and to evaluate the potential pseudo-specificity of these approaches.

Total Pages: 201-221 (21)

Purchase Chapter  Book Details


.Frontiers in Anti-infective Drug Discovery.
.Frontiers in Drug Design and Discovery.
.In Silico and In vitro Approaches to Screen the Anti-TB Activity of Benzothiazole Analogs.
.Anti-Obesity Drug Discovery and Development.